 Effects recombinant human aplastic anemia phase I/II study patients aplastic anemia recombinant human toxicity biologic effects multipotential hematopoietic growth factor subcutaneous bolus injections days increase platelet counts patient increase reticulocyte counts patients blood leukocyte patients median due increase number neutrophils eosinophils lymphocytes monocytes patients bone marrow cellularity substantial improvement peripheral blood counts Mild side effects headache flushing patients low-grade fever patients Transient thrombocytopenia discontinuation treatment patient conclusion hematopoiesis patients aplastic anemia lasting effects